Specifications include, but are not limited to: A. To insure the integrity of the Arkansas Racing Commission, the following screening methods, or DFA-Racing Commission approved equal, must be utilized: 1. Urine or blood samples screened using: a. Combination approach of rotating thin-layer chromatography, immunoassay screening, or instrumental screening using Liquid Chromatography/Diode Array (LC-DAD) detection or Gas Chromatography/Mass Spectrometry. b. Equine urine screening consisting of fifteen (15) immunoassay tests and one (1) additional test performed by TLC, HPLC, or GC/MS. c. Canine urine screening consisting of five (5) immunoassay tests and two (2) additional test performed by TLC, HPLC, or GC/MS. 2. HPLC, ELISA, GC/MS or Thin-Layer Chromatography (TLC) hydrolysis-acid extraction, salt-out extraction, and enzyme hydrolysis basic extraction techniques. a. This method will ensure coverage for commonly encountered therapeutic medications, such as the Non-Steroidal Anti-inflammatory Drugs (NSAID’s) as well as a large diversity of compounds such as Ephedrine, Methocarbamol, Lidocaine, Procaine, Atropine, DMSP, etc. 3. Enzyme Linked Immunosorbent Assay (ELISA) using a minimum of fifteen (15) immunoassay test, on a non-pooled basis, to address detection of trace amounts of RCI Class l, ll, and lll drugs. 4. Instrumental screening using either Liquid Chromatography/Diode Array Detection (LC-DAD) or Gas Chromatography/Mass Spectrometry (GC/MS) to detect a large diversity of compounds of all RCI drug classes. B. Positive results must be confirmed by GC/MS or Liquid Chromatography with Tandem Mass Spectrometry (LC/MS/MS). Expended panels must be included in the pricing. C. Contractor shall, without additional compensation, and as determined by DFA-Racing Commission, correct or revise any: 1. Errors 2. Omissions 3. Other deficiencies in its deliverables and laboratory services